Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Maire Osborn, Ph.D., Associate Director of Neuro Discovery at Dicerna, will present new nonclinical data discussing the Company’s GalXC-Plus™ RNAi technology as part of the sixth annual Oligonucleotide and Precision Therapeutics (OPT) Virtual Congress taking place March 30-31, 2021.
The keynote presentation titled, “GalXC-Plus: Cell-Type Targeted Therapeutic Oligonucleotide Delivery in the CNS,” will take place on Tuesday, March 30, 2021 at 10:50 a.m. ET. and will detail new nonclinical data on targeted, cell-specific delivery to the central nervous system (CNS), as well as CNS-wide delivery and durability of action, using Dicerna’s GalXC-Plus technology.
The presentation will be made available on the Events & Presentations page of Dicerna’s corporate website following the presentation.
About Dicerna's GalXC™ RNAi Technology Platform
Dicerna’s proprietary GalXC™ RNA interference (RNAi) platform aims to advance the development of next-generation RNAi-based therapies designed to silence genes implicated in disease. Investigational therapeutics developed using our flagship GalXC technology utilize a proprietary N-acetyl-D-galactosamine (GalNAc)-mediated structure of double-stranded RNA molecules that are designed to bind specifically to receptors on liver cells, leading to selective hepatocyte internalization and access to the RNAi machinery within the cells. Dicerna is continuously innovating and exploring new applications for RNAi technology beyond GalNAc-mediated delivery to the liver, including alternative RNA structures and fully synthetic ligands that target other tissues and enable new therapeutic applications, referred to as GalXC-Plus™.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using our proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna’s GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of our flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to our own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world’s leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and our collaborative partners, we currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. At Dicerna, our mission is to interfere – to silence genes, to fight disease, to restore health. For more information, please visit www.dicerna.com.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements pertaining to the Company’s planned participation in the Oligonucleotide and Precision Therapeutics Virtual Congress, which may include discussion of the Company’s business and operations, including the discovery, development and commercialization of product candidates and novel technologies, and the possible therapeutic potential thereof, which may be done with reference to the general success of our collaborations with our current partners and the potential for possible future collaborations. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those relating to our preclinical research and clinical programs and other risks identified under the heading “Risk Factors” included in our most recent Form 10-K filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.
GalXC™ and GalXC-Plus™ are trademarks of Dicerna Pharmaceuticals, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005300/en/
Contacts:
Amy Trevvett
+1 617-612-6253
atrevvett@dicerna.com
